Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102.Results from the randomized, double-blind, placebo-controlled single ascending dose (SAD) cohort of the Phase 1 healthy volunteer trial and initial results from the multiple ascending dose (MAD) cohort were shared in a presentation at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.The Phase 1 trial included SAD cohorts from 10 mg to 200 mg and MAD cohorts of 10 mg ...